Dr. Miver Erem Tokuş
NeurosurgeryVerified
- 24+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Brain Surgery
Resection of medulloblastoma
What resection of medulloblastoma involves, how neurosurgeons perform posterior fossa craniotomy with neuro-navigation and intraoperative monitoring, what evidence says on extent of resection, comparative costs in Turkey against the UK, US and Germany, post-operative recovery milestones, potential complications such as cerebellar mutism, and how to evaluate specialist paediatric and adult neurosurgical teams abroad.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Brain Surgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Resection of Medulloblastoma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Resection of medulloblastoma in Turkey: what it is and surgical goals
Resection of medulloblastoma is a major neurosurgical operation to remove an embryonal, fast-growing tumour in the posterior fossa of the brain, most often in the cerebellum or fourth ventricle. While most prevalent in children, it also occurs in adults. The primary goal of surgery is maximum safe cytoreduction—removing as much tumour as possible while safeguarding essential brainstem functions, motor coordination and cranial nerves. For international families, resection of medulloblastoma in Turkey provides access to specialised neurosurgical departments equipped with modern intraoperative guidance. For an overview of cranial procedures, see our guide to neurosurgery treatments in Turkey.
Surgical resection is the first critical phase in multidisciplinary management. Complete or near-complete excision relieves intracranial pressure from obstructive hydrocephalus and provides essential tissue for molecular subgrouping (WNT, SHH, Group 3, Group 4), which dictates subsequent radiotherapy and chemotherapy.
How resection of medulloblastoma is performed step by step
The procedure is carried out under general anaesthesia with the patient in a prone or modified concord position, the head secured in a rigid fixation frame. Modern operating theatres employ continuous intraoperative neurophysiological monitoring (IONM) to track brainstem auditory evoked potentials, motor pathways and lower cranial nerves (VII, IX, X, XII) throughout surgery.
A midline suboccipital craniotomy is performed at the back of the skull to access the posterior fossa. Under high magnification, the neurosurgeon usually employs a telovelar approach through the cerebellomedullary fissure into the fourth ventricle, avoiding division of the cerebellar vermis. Using stereotactic neuronavigation and an ultrasonic aspirator (CUSA), the tumour is debulked and separated from surrounding cerebellum and the brainstem floor. Haemostasis is achieved with microbipolar cautery, CSF circulation is re-established, and the dura is closed watertight.
Does surgical resection cure medulloblastoma? What the clinical evidence says
Clinical guidelines from the European Association of Neuro-Oncology (EANO) and Society for Neuro-Oncology (SNO) emphasize that surgical resection alone is rarely curative. Medulloblastoma is a high-grade malignant tumour with an innate tendency to disseminate through cerebrospinal fluid. However, surgical debulking is a vital prognostic factor.
Achieving gross total resection (GTR) or near-total resection (NTR, residual tumour under 1.5 cm² on post-operative MRI) substantially improves progression-free survival when combined with risk-adapted craniospinal irradiation and chemotherapy. Contemporary protocols prioritise maximum safe resection: if tumour tissue infiltrates the brainstem floor, leaving a thin rim of tissue is widely accepted to avoid devastating neurological deficits.
Resection of medulloblastoma cost: Turkey compared with the UK, US and Germany
Posterior fossa tumour surgery is an advanced inpatient cranial procedure. Pricing reflects neurosurgical team fees, operating theatre utilisation, neuronavigation, neurophysiological monitoring, paediatric or adult intensive care (ICU), and ward stay. The ranges below represent approximate costs and are not binding quotes.
| Country | Approximate cost range |
|---|---|
| Turkey | €12,000 – €28,000 |
| United Kingdom | €30,000 – €65,000 |
| United States | €60,000 – €140,000 |
| Germany | €28,000 – €55,000 |
The total resection of medulloblastoma price depends on ICU duration, emergency hydrocephalus interventions (such as an external ventricular drain or shunt), and advanced molecular profiling. Packages in Turkey generally include surgery, anaesthesia, routine ICU days, basic post-operative imaging and transfers. To receive an itemised assessment based on your MRI scans, request a free quote.
Extent of resection: gross total resection vs subtotal resection
Surgical success is classified by residual tumour volume on contrast MRI within 72 hours. While skull-base lesions may use anterior corridors like transnasal resection of tumor, medulloblastoma requires suboccipital access.
| Technique / Resection extent | Best suited to | Typical limits |
|---|---|---|
| Gross total resection (GTR) | Tumours confined to cerebellar hemispheres or 4th ventricle | Cannot be achieved safely when tumour infiltrates brainstem nuclei |
| Subtotal / Near-total resection (STR / NTR) | Tumours adherent to the 4th ventricle floor or cranial nerves | Leaves residual mass requiring intensified adjuvant oncology protocols |
| CSF diversion (ETV or shunt) | Acute obstructive hydrocephalus with raised intracranial pressure | Manages intracranial pressure only; does not resect tumour mass |
Modern surgical consensus avoids radical removal if it compromises neurological function. Subtotal resection paired with adjuvant therapy is the standard approach when critical brainstem structures are involved.
Who is a candidate for posterior fossa tumour resection?
Resection is indicated for nearly all patients presenting with a suspected posterior fossa embryonal tumour who can tolerate general anaesthesia. Symptoms typically arise from raised intracranial pressure or cerebellar mass effect: morning headaches, vomiting, lethargy, unsteady gait (ataxia) and double vision. Urgent surgery is required if acute hydrocephalus threatens neurological compromise.
Patients not suited for immediate radical craniotomy include those with uncorrectable coagulopathies, severe systemic sepsis or profound hemodynamic instability. In such cases, temporary CSF diversion via an external drain or shunt is performed first to stabilise the patient before definitive resection.
What do post-operative scans and pathology reveal?
In cranial neuro-oncology, results are assessed via neuroimaging and histopathology rather than cosmetic comparisons. Contrast-enhanced MRI of the brain and spine is conducted within 24 to 72 hours of surgery. Imaging during this window accurately distinguishes residual tumour from subsequent post-surgical granulation and reactive enhancement.
Resected tissue undergoes histology and advanced molecular profiling under WHO criteria. Tumours are classified into four molecular subgroups: WNT, SHH, Group 3, or Group 4. Combined with post-operative MRI residual status and CSF cytology for spinal drop metastases, molecular profiling defines the patient's risk category and guides radiation and chemotherapy dosing.
Recovery timeline and hospital stay in Turkey
Recovery occurs in structured clinical stages following posterior fossa surgery:
- Days 1–3 (Intensive care): The patient is monitored in the neuro-ICU with continuous tracking of intracranial pressure, neurological status, blood pressure and fluid balance. Swallowing function is evaluated before oral intake resumes.
- Days 4–7 (Surgical ward): Transfer to the inpatient ward. Physical therapy begins with gentle mobilisation and balance exercises. Early post-operative MRI confirms resection extent.
- Weeks 2–3 (Outpatient recovery): Stitches are removed between days 10 and 14. Patients stay near the hospital for wound checks and neurological review before receiving fit-to-fly clearance.
- Weeks 4–6 (Adjuvant oncology): Resection of medulloblastoma recovery transitions to adjuvant craniospinal irradiation and chemotherapy once the craniotomy incision is soundly healed.
For international families, resection of medulloblastoma Turkey arrangements typically require 18 to 25 days in total to ensure safe wound healing and complete post-operative evaluations before the flight home.
Potential surgical risks, posterior fossa syndrome and complications
Craniotomy for medulloblastoma carries significant recognised risks. Authoritative organisations such as the National Health Service (NHS) and the American Association of Neurological Surgeons (AANS) highlight general surgical risks—infection, haemorrhage, deep vein thrombosis and anaesthetic complications—alongside specific posterior fossa risks:
- Posterior fossa syndrome (cerebellar mutism): Developing in 10% to 25% of paediatric cases between 1 and 4 days post-operatively, causing temporary speech loss, emotional lability, hypotonia and ataxia. Deficits improve over months, though subtle impairments may persist.
- Cerebrospinal fluid leak: Incomplete dural healing can cause CSF leakage or pseudomeningocele, occasionally requiring lumbar drainage or revision.
- Persistent hydrocephalus: In 20% to 30% of patients, post-operative scarring impairs CSF reabsorption, requiring a permanent ventriculoperitoneal (VP) shunt.
- Neurological deficits: Traction on lower cranial nerves or cerebellar nuclei can cause swallowing difficulties (dysphagia), diplopia or balance problems.
How to choose a neurosurgical centre and multidisciplinary red flags
Complex posterior fossa surgery demands a tertiary hospital equipped with 24/7 neuro-intensive care, intraoperative neurophysiological monitoring, stereotactic neuronavigation, and neurosurgeons with specific suboccipital microsurgical experience. Because surgery is only the first step, the hospital must feature an active multidisciplinary tumour board including neuro-oncologists, radiation therapists and neuropathologists.
Key red flags include:
- Clinics without dedicated paediatric or neurovascular ICU facilities.
- Claims of surgical cure without acknowledging required adjuvant radiation or chemotherapy.
- Absence of intraoperative monitoring equipment or protocols for acute hydrocephalus.
- Lack of molecular neuropathology facilities for WHO subtyping.
- Pressure to book without a comprehensive written treatment plan.
Read how it works when coordinating care abroad, and request an assessment on our free quote page.
Key questions to ask your neurosurgical and oncology team
Before travelling for surgery, ask the following questions during your clinical consultation:
- How many posterior fossa tumour resections does the neurosurgical team perform annually?
- Is continuous intraoperative neurophysiological monitoring (IONM) used throughout the procedure?
- What is your protocol for managing acute post-operative hydrocephalus or cerebellar mutism?
- Does the hospital provide molecular subgrouping (WNT, SHH, Group 3, Group 4) under current WHO guidelines?
- What is the expected length of ICU and ward stay?
- How will surgical summaries, imaging discs and pathology slides be shared with our home oncologist?
For further guidance on neuro-oncological care across our neurosurgery treatments in Turkey network, our team is available to assist.
Conditions treated with Resection of Medulloblastoma
Hospitals with Neurosurgery in Turkey
Frequently asked questions
Resection of medulloblastoma is the surgical removal of a malignant, fast-growing embryonal tumour located in the posterior fossa of the brain, typically arising in the cerebellum or fourth ventricle. Performed via a suboccipital craniotomy under magnification, the primary surgical objective is maximum safe tumour debulking while protecting essential brainstem pathways and vital neurological functions.
Surgery alone rarely cures medulloblastoma because microscopic tumour cells can migrate through cerebrospinal fluid pathways. However, complete or near-total surgical resection is a foundational prognostic determinant. Successful surgical debulking relieves intracranial pressure, facilitates precise molecular diagnosis, and substantially improves the efficacy of subsequent adjuvant radiotherapy and chemotherapy protocols.
In Turkey, surgical resection of medulloblastoma typically ranges between €12,000 and €28,000, compared with €30,000 to €65,000 in the UK and higher in the US. Final pricing depends on intensive care unit duration, the necessity of hydrocephalus management such as shunting, operating equipment requirements, and specialised molecular neuropathology testing.
Before surgery, MRI scans display a prominent mass in the posterior fossa frequently compressing the fourth ventricle and causing obstructive hydrocephalus. Contrast-enhanced MRI within 72 hours of surgery confirms whether gross total resection was achieved, quantifies any residual tumour volume, and verifies restored cerebrospinal fluid circulation.
Initial recovery requires one to three days in a neuro-intensive care unit, followed by three to five days on a neurosurgical ward. Mobilisation, physical therapy and swallowing evaluations begin promptly. Most patients spend two to three weeks recovering locally before travelling home, after which they prepare for adjuvant oncological therapies.
During surgery, the patient is completely unconscious under general anaesthesia and feels nothing. Post-operatively, surgical site pain, neck stiffness and headache are common as tissues heal. These discomforts are closely monitored and managed using intravenous analgesics, anti-inflammatory medications and anti-nausea treatments, gradually tapering to mild oral painkillers.
Long-term outlook depends on patient age, extent of resection, metastatic stage and molecular subgroup (WNT, SHH, Group 3, or Group 4). Standard-risk patients who undergo gross total resection followed by risk-adapted craniospinal irradiation and chemotherapy achieve favourable long-term disease control, while high-risk profiles require intensified multimodal therapy.
Posterior fossa craniotomy is a complex neurosurgical intervention carrying known risks, including bleeding, infection, CSF leak, hydrocephalus and posterior fossa syndrome (cerebellar mutism). Safety is optimised by operating in tertiary centres utilising continuous intraoperative neurophysiological monitoring, advanced neuronavigation and dedicated neuro-intensive care support.
Gross total resection removes all visible tumour, offering optimal survival prospects. However, if tumour tissue invades the brainstem floor or cranial nerves, neurosurgeons perform subtotal or near-total resection to avoid permanent neurological disability. Adjuvant radiotherapy and chemotherapy are subsequently adjusted to address residual microscopic or macroscopic disease.
Patients and accompanying family members should plan for a total stay of 18 to 25 days. This duration accommodates pre-operative neuro-imaging, surgical planning, hospital admission of 5 to 8 days (including ICU care), suture removal, and follow-up checks until obtaining written fit-to-fly clearance.
Patient stories